A blood test that detects tumor DNA circulating in the bloodstream may help select the most effective treatment options for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. BERLIN — For years, scientists have ...

Post-transplant survival. (A) Overall and (B) recurrence-free survival for the entire cohort. The dotted lines indicate the 95% confidence interval for the survival curves. A personalized blood test ...

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is circulating tumor DNA, often called ctDNA, which is gaining attention in ...

A growing body of research underscores the value of ctDNA-based MRD testing to identify residual or recurring cancer in solid tumors. By detecting trace amounts of tumor-derived DNA in the bloodstream ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a ...

Although the oncology community is buzzing with the potential of circulating tumor DNA (ctDNA) to revolutionize breast cancer ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, ...

Baseline ctDNA negativity or on-treatment clearance in anal squamous cell carcinoma correlated with 100% one-year overall survival and no local recurrence, whereas post-treatment positivity predicted ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology ...